Inqovi

• Inqovi is an oral medication approved for treating myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML).
• It combines decitabine, a hypomethylating agent, with cedazuridine, an inhibitor that allows for oral administration.
• The drug works by reactivating genes critical for normal cell growth and differentiation, helping to restore healthy blood cell production.
• Benefits include improved blood counts, reduced transfusion dependence, and the convenience of an oral dosage form.
• Patients should be aware of potential side effects, including myelosuppression and gastrointestinal issues, and receive regular medical monitoring.

What is Inqovi?

Inqovi is an oral prescription medicine used to treat adults with myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML). It is a fixed-dose combination of two active ingredients: decitabine and cedazuridine. Decitabine is a hypomethylating agent, a type of chemotherapy that works by altering DNA methylation patterns in cancer cells. Cedazuridine is an inhibitor of cytidine deaminase, an enzyme that would otherwise break down decitabine in the gut, thereby enabling decitabine to be absorbed orally and reach therapeutic levels in the body.

This innovative formulation allows patients to receive treatment at home, reducing the need for frequent clinic visits associated with intravenous administration of similar drugs. The development of Inqovi represents a crucial step in improving the quality of life for individuals managing these challenging blood disorders.

How Inqovi Works and Its Medical Uses

The mechanism behind Inqovi drug information centers on its active component, decitabine. Decitabine is a nucleoside metabolic inhibitor that incorporates into DNA and inhibits DNA methyltransferase enzymes. This inhibition leads to hypomethylation of DNA, which can reactivate genes involved in the regulation of cell differentiation and proliferation. In cancer cells, certain genes that suppress tumor growth or promote normal cell development can become “silenced” by excessive methylation. By reversing this methylation, Inqovi helps to restore normal gene function, leading to the production of healthy blood cells and reducing the growth of abnormal cells.

Inqovi is primarily used for the treatment of adult patients with myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML). MDS refers to a group of disorders where the bone marrow fails to produce enough healthy blood cells, often leading to anemia, infections, and bleeding. CMML is a rare blood cancer that shares features of both MDS and myeloproliferative neoplasms. According to the American Cancer Society, an estimated 10,000 to 20,000 new cases of MDS are diagnosed in the United States each year, highlighting the significant need for effective treatments. The oral formulation of Inqovi provides a convenient and effective option for managing these conditions, contributing to better patient adherence and overall treatment outcomes.

Inqovi: Benefits and Potential Side Effects

The introduction of Inqovi offers several key benefits for patients with MDS and CMML. One of the most significant advantages is its oral administration, which allows patients to take the medication at home, reducing the burden of frequent hospital visits for intravenous infusions. This convenience can greatly improve a patient’s quality of life and adherence to treatment. Clinically, Inqovi has been shown to improve blood counts, potentially reducing the need for blood transfusions and mitigating symptoms associated with low blood cell counts, such as fatigue and increased risk of infection.

However, like all medications, Inqovi carries potential side effects. Understanding Inqovi side effects and benefits is crucial for patients and healthcare providers. The most common side effects are related to myelosuppression, meaning a decrease in bone marrow activity, which can lead to:

• Fatigue
• Nausea and vomiting
• Diarrhea or constipation
• Low white blood cell counts (neutropenia), increasing infection risk
• Low red blood cell counts (anemia), causing fatigue and weakness
• Low platelet counts (thrombocytopenia), leading to bruising or bleeding

More serious side effects can include severe infections, febrile neutropenia, and worsening of pre-existing heart conditions. Patients receiving Inqovi require regular monitoring of their blood counts and overall health by a healthcare professional to manage potential side effects promptly and effectively. It is essential for patients to report any new or worsening symptoms to their doctor immediately.